SCHEMBL4675173

SCHEMBL4675173

O=C(C=C(O)c1nc[nH]n1)c1ccoc1Oc1ccccc1Cl

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.33
POLB P06746 2/20 0.33
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP1A1 P04798 1/20 0.33
ABCB1 P08183 1/20 0.33
CYP1B1 Q16678 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RECQL P46063 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CXCL8 P10145 1/20 0.33
TRPM4 Q8TD43 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674906 0.88 CYP1A1 (0.40) RAB9APOLBMAPTSMN1; SMN2KMT2A
SCHEMBL4676663 0.86 CYP1A1 (0.36) RAB9AMAPTSMN1; SMN2KMT2ACYP1A1
SCHEMBL4674286 0.85 RXRA (0.33) CYP1A1ABCB1CYP1B1
SCHEMBL4672847 0.84 CXCL8 (0.36) RAB9APOLBMAPTSMN1; SMN2KMT2A
SCHEMBL4674141 0.83 CDH1 (0.33) RAB9AKMT2ACYP1A1ABCB1CYP1B1
SCHEMBL4676769 0.82 CXCL8 (0.36) RAB9APOLBMAPTSMN1; SMN2KMT2A
SCHEMBL4673044 0.82 KDM4C (0.36) KDM4ETDP1KDM4CABL1
SCHEMBL4672505 0.81 MAPT (0.33) RAB9APOLBMAPTSMN1; SMN2KMT2A
SCHEMBL4679724 0.79 CYP1A1 (0.30) CYP1A1ABCB1CYP1B1
SCHEMBL4674086 0.79 CYP1A1 (0.36) RAB9APOLBMAPTSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 RAB9A 2021/4885POLB 58/4885MAPT 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.